Izicelo Zemitholampilo ye-Salmon PDRN ku-Aesthetic Medicine: Ngale Kwe-“Salmon Sperm” Ukulandisa 

Incazelo ye-Meta
Hlola isayensi engemuva kwe-Salmon PDRN ukuze uthole ukululama kwangemva kwe-laser, ukulawula ukuvuvukala, nezixazululo zokulwa nokuguga. Umhlahlandlela osebenzayo wemikhiqizo ye-skincare kanye nochwepheshe bezobuhle bezokwelapha.

Isingeniso: Kungani i-PDRN Idinga Ukubukeka Kwesibili

NgoJanuwari 2026, isihloko sezindaba saphinda sathatha ukunaka komhlaba wonke: "Iqiniso Mayelana Nobuso Be-Salmon Sperm" . Kwakuvusa imizwa, igciwane, futhi-njengezikhathi eziningi ezibangelwa amagciwane-aphuthelwe iphuzu ngokuphelele.

Ngemuva kwegama elivusa inkanuko kunelinye lamakhulu ama-biomolecule avuselelayo ahlukile ngomshini ukungena emithi yobuhle emashumini eminyaka. I-Polydeoxyribonucleotide (PDRN) ayisona nje esinye isithako se-hydrating noma i-collagen booster. Isebenza ngokusebenzisa izindlela ezimbili, ezihambisanayo—ukwenziwa kusebenze kwe-extracellular receptor kanye ne-intracellular nucleotide salvage—ukuthi kungabikho esinye isithako sobuhle esiphindaphindayo .

Nokho ukudideka kusaqhubeka. Odokotela bahlanganisa i-PDRN ne-polynucleotide (PN). Imikhiqizo imakethe "i-DNA skincare" ngaphandle kokuqonda ukunqanyulwa kwesisindo samangqamuzana. Izilawuli e-China nase-U.S. zihamba ngezigaba ezihlukene, zidala ubuhlungu bekhanda bokuthobela ukwethulwa komkhiqizo emhlabeni jikelele .

Lesi sihloko sibhalelwe abaklami, abaqondisi bemitholampilo, namasu omkhiqizo abadinga ukwedlula i-hype. Sihlola:

• I Indlela yokwamukela i-A2A ehlukanisa i-PDN ku-PN nezici zokukhula

• Ubufakazi obuqondene nenqubo izinhlelo zokusebenza ze-post-laser kanye ne-microneedling

• Ukuguqulwa kwamagama—kungani i-“Marques Polynucleotide Cutoff” ishintsha indlela olebula ngayo imikhiqizo

• Izinyathelo ezibalulekile zokulawula e-China nokuthi zisho ukuthini ngokungena emakethe ka-2026–2027

Akukho ukuzwa. Azikho izimangalo "zezimangaliso". Isignali nje, ehlukene nomsindo.

1. Ukuchaza I-Molecule: Kungani i-PDRN ne-PN Zingashintsheki

1.1 Ukungenelela Kwamagama Ka-2025

Kwaphela amashumi amathathu eminyaka, kwasetshenziswa izincwadi zobuhle I-PDN futhi PN ngokushintshana. Zombili zisuselwa ku-DNA. Zombili zivela ku-salmon noma i-trout. Zombili zisetshenziselwa imijovo kanye nezihloko.

Lokhu bekuyinkinga. Odokotela bakhethe imikhiqizo ngokusekelwe esimeni somkhiqizo esikhundleni sokufaneleka kwamangqamuzana, okuholela emiphumeleni ephansi kanye nezincwadi zomtholampilo ezididekile .

NgoJanuwari 2025, iqembu labacwaningi bamazwe ngamazwe eliholwa nguMarques et al. uphakamise isixazululo sesakhiwo: I-Marques Polynucleotide Cutoff.

• I-PDN (Polydeoxyribonucleotide): Isisindo samangqamuzana < 1500 kDa. Amaketanga amafushane. I-A2A receptor agonist. Indlela eyinhloko: uphawu lwe-pharmacologic + nucleotide salvage.

• PN (I-Polynucleotide): Isisindo samangqamuzana ≥ 1500 kDa. Amaketanga amade. Yakha i-viscous hydrogel. Indlela eyinhloko: mechanical volumizing + hydration .

Umthelela womtholampilo:
Uma umkhiqizo wakho uncike uphawu lokulwa nokuvuvukala, ukusebenza kwe-fibroblast, noma i-VEGF-mediated angiogenesis, usebenzisa i-PDRN—kungakhathaliseki ukuthi ilebula ithini. Uma umkhiqizo wakho uncike ukugcwaliswa kwe-viscoelastic kanye ne-hydration eqhubekayo, usebenzisa i-PN .

1.2 Ukwehlukaniswa Kwesakhiwo Okuthinta Ukusebenza

Okubalulekile okuthathayo kumabhrendi:
Ukusebenzisa i-“PN” ukuchaza ukwakheka kwe-PDRN yochungechunge olufushane akukhona nje ukuthi akunembile—kudukisa odokotela mayelana nendlela elindelekile kanye nobude bokusebenza.

2. Izindlela Zesenzo: Indlela Ekabili Echaza I-PDRN

Ngokungafani nama-biomolecules amaningi wobuhle asebenzayo imiphumela ye-eksisi eyodwa, I-PDN isebenza nge izindlela ezimbili ezizimele kodwa ezisebenzisanayo .

2.1 Indlela Yokuqala: I-A2A Receptor Activation

I-PDRN i-agonist ekhethiwe ye- i-adenosine A2A receptor-i-G-protein-coupled receptor evezwa kuma-fibroblasts, amaseli e-endothelial, namaseli omzimba.

Izimbangela ezibophezelayo:

• ↑ ikhempu (i-cyclic adenosine monophosphate)—isignali ye-intracellular eyenza kusebenze i-A2A

• ↓ Ukudluliselwa kwe-NF-κB-yehlisa ukulotshwa kwama-cytokines ane-pro-inflammatory (TNF-α, IL-1β, IL-6)

• ↑ I-VEGF (i-vascular endothelial growth factor)—ithuthukisa i-angiogenesis kanye nokugcwaliswa kwezakhi ezicutshini eziphulukisayo

• ↑ Ukuhlanganiswa kwe-Collagen I/III-kulamula ngokunciphisa i-MMP-1 kanye nokulawulwa kwe-TGF-β

Ubufakazi obuvela ezinkambini eziseduze:
Ngo-2025 IsayensiDirect ucwaningo nge-ulcerative colitis yakuqinisekisa lokho ukuphathwa ngokubambisana kwe-DMPX (umphikisi we-A2A) iqedwe ngokuphelele I-PDRN's anti-inflammatory kanye ne-VEGF-upregulating effects. Lena indlela efanayo yokwamukela eyenziwa yasebenza ku-dermal fibroblasts .

Ukuhumusha komtholampilo:
Lapho i-PDRN ilethwa esikhumbeni esisengozini—kungaba ngomjovo, i-microneedling, noma i-laser-assisted infusion— ikhombisa ngenkuthalo izicubu ukuthi zisuke kumodi yokuvuvukala ziye kumodi yokulungisa eyandayo. Lokhu akukona ukudla okwenziwayo. Yilokhu ukungenelela kwe-pharmacologic .

2.2 Indlela Yesibili: Salvage Pathway Nucleotide Supply

Izicubu ezilimele kanye ne-hypoxic zibhekene nenkinga yamandla. I-novo nucleotide synthesis—indlela yeseli ezenzakalelayo yokwakha izandulela ze-DNA—idinga umoya-mpilo futhi ibiza ngamandla .

I-PDN inikeza enye indlela.

Lapho i-PDRN idlula ukuwohloka kwe-enzymatic, iyakhululwa i-bioavailable nucleosides nama-nucleotide ukuthi bangene indlela yokuhlanza. Lokhu kusebenzisa kabusha izisekelo ezakhiwe kusengaphambili ngokuqondile ku-DNA synthesis, kweqa umzila we-de novo obiza amandla .

Kungani lokhu kubalulekile emithini yobuhle:

• Isikhumba se-post-laser sinjalo ukucindezeleka kwe-metabolic kanye ne-hypoxic

• Ama-fibroblasts adinga ama-nucleotide ukuze andise futhi ahlanganise i-collagen

• I-PDRN inikeza izinto zokusetshenziswa ngokushesha ngenkathi kanyekanye isayina nge-A2A ukuya lawula imishini yokulungisa

Asikho esinye isithako sobuhle esenza kokubili.

3. Izicelo Zomtholampilo: Ubufakazi Ngenqubo

3.1 I-Post-Laser Resurfacing: Inkomba Esekelwe Kakhulu

Inkinga:
I-Fractional laser resurfacing idala ukulimala okushisayo okulawulwayo. Nakuba kuphumelela ekulungiseni kabusha, kuyayenga i-erythema ende, i-edema, nokuphelelwa yisikhathi kwesiguli. Ngokomlando, odokotela babekwamukela lokhu njengokungenakugwenywa .

Isixazululo se-PDN:
Ucwaningo lwemodeli yamagundane lwango-2017 olwenziwe ngu-Yu no-Lee lubonise lokho Amanxeba elaser alashwe nge-PDRN akhombise ukwanda kakhulu kwamaseli e-VEGF-positive kanye nama-CD31-positive microvessels uma kuqhathaniswa nezilawuli. I-re-epithelialization isheshisiwe. Ukuvuvukala kwehle ngokushesha.

Iparele lomtholampilo:
I-PDRN "ayivimbeli" ukulimala kwe-laser-it icindezela isigaba sokuvuvukala futhi ikhulisa isigaba sokukhula. Iziguli namanje red, kodwa phuma ububomvu ngokushesha .

Ukuqonda kwephrothokholi ka-2026:
Imitholampilo ehamba phambili yokuvuselela kabusha yase-U.S. manje isebenzisa i-PDRN njenge- isengezo ozikhethela sona ukuphakamisa ubuso kanye nezinqubo ze-laser-hhayi "njengesimangaliso" esizimele, kodwa njenge-a isithuthukisi somsindo webhayoloji yendawo yokwelapha .

3.2 I-Microneedling nge-PDRN: I-Device-Assisted Synergy

I-Microneedling iyadala ama-microchannel aqondile ezidlula umgoqo we-stratum corneum. Lokhu akukhona nje ukuhambisa okwenziwayo—i i-micro-injury ngokwayo ivula ama-platelet futhi ibuthe amaseli okukhanda .

Lapho i-PDN i ifakwe ngesikhathi se-microneedling, izindlela ezimbili ziqondaniswe:

1. Okomzimba: I-PDRN ifinyelela ku-dermis ngaphandle kokuthembela ekwakhiweni okungabazekayo kwe-"transdermal".

2. I-Biological: Ukuvuvukala okubangelwa yi-Microneedling imodulwe ngenkuthalo nge-PDRN's A2A agonism

Imiphumela ebhekiwe (kubikwe emtholampilo):

• Ubude besikhathi se-erythema yangemva kwenqubo eyehlisiwe

• Ukubuyela ngokushesha ekuzimonyoni (ngokuvamile amahora angu-24 vs. 48–72)

• Ukuthuthuka kokuthungwa okuthuthukisiwe ochungechungeni lweseshini engu-3–6

I-Caveat:
I-PDRN yesihloko isetshenziswa esikhumbeni esingaguquki ngaphandle Ukulethwa kosizo kusasele kuyimpumelelo engenabufakazi. Odokotela besikhumba okwaxoxwa nabo ngoFebhuwari 2026 bazwakalisa ukungabaza ukuthi izinzuzo ezibonakalayo ezivela kumaserum e-PDRN “ekhaya” atholakala ku-PDRN ngokwayo—izithako ezisekelayo zingase zibe ama-agent eqiniso asebenzayo .

3.3 Izicelo Zokulwa Nokuvuvukala: Ngalé Kwenqubo Yangemuva

Ukuvuvukala okungapheli kwebanga eliphansi kuyabonakala isikhumba esigugayo, isikhumba esizwelayo, kanye nama-phenotypes athambekele e-rosacea. Ama-ejenti endabuko e-anti-inflammatory (i-corticosteroids, i-calcineurin inhibitors) ayasebenza kodwa awafaneleki ukunakekelwa kwesikhathi eside .

I-PDRN inikeza a non-steroidal, physiologically regulated indlela yokulwa nokuvuvukala.

Ukusakaza kobufakazi:

• Ukusebenza kwe-A2A icindezela i-NF-κB, inciphisa ukulotshwa kwe-TNF-α ne-IL-6

• I-IL-10 (i-anti-inflammatory cytokine) ilawulwa

• Ukufakwa kwe-VEGF isekela ubuqotho be-vascular, inciphisa i-erythema eqhubekayo

Ithagethi yomtholampilo:
Iziguli ezingakwazi ukubekezelela ama-retinoids ngenxa yobuthakathaka besithiyo zingazuza kuzo I-PDRN njenge-ejenti esekela ukulungiswa, esetshenziswa ngokuhambisana ne-exfoliation emnene kanye ne-photoprotection .

4. Ukuma Kwendawo Elawulayo: Isimo Sango-2026 Nemithelela Yamasu

4.1 I-China: IMilestones ye-NMPA

Kusukela ngo-Ephreli 2025, izinkampani eziyisikhombisa kuphela yayiqede ukubhaliswa kwefayela eliyinhloko ledivayisi yezokwelapha ye-PDN ne-NMPA yaseChina. I-Lingmei Biotechnology (Hubei Lingmei) yaba yi- eyesikhombisa ngo-Ephreli 16, 2025 .

Umugqa wesikhathi:

• Ukubhaliswa kwefayela okuyinhloko: 2025 Q2

• Ukuqedwa kokuhlolwa komtholampilo: Kulinganiselwe ngo-2025 Q3

• Ukugunyazwa kwedivayisi yezokwelapha ye-Class III ehlongozwayo: 2026 Q4

Kusho ukuthini lokhu:

• Ayikho i-PDRN ethobelanayo yomjovo etholakalayo njengamanje e-China

• Imikhiqizo ethengiswayo ithembele kuyo ukubhaliswa kwezimonyo noma izintuba ze-e-commerce eziwela umngcele

• Imikhiqizo yokuqala enamadivayisi agunyaziwe e-Class III azothwebula isabelo semakethe esibalulekile ekuqaleni ngasekupheleni kuka-2026

Ukuthuthukiswa okuhambisanayo:
I-SEOHO LAB iqede ukubhaliswa kwelayisense yenhlanzeko ye-NMPA ye Inani eliphakeme lempahla ye-PDRN ngoDisemba 2025, ukususa imigoqo yokuthumela ngaphandle izimonyo-ibanga Imikhiqizo ye-PDN .

I-Takeaway yamaqhinga:
I-PDRN ejovwayo kanye ne-PDRN yesihloko izindlela zokulawula eziphambukayo. Amabhrendi aqondise imigudu yezokwelapha kufanele abeke phambili Ukubhaliswa kwedivayisi ye-Class III. Amabhrendi aqondise iziteshi zabathengi angaqhubeka ngokusebenzisa Isaziso sezimonyo se-NMPA, kodwa kufanele sikugweme ukwenza izimangalo ezifana nezidakamizwa .

4.2 I-United States: Isimo se-FDA

Awukho umkhiqizo we-PDRN ojovwayo ogunyazwe yi-FDA ukuze usetshenziswe ngobuhle .

Ukusetshenziswa komtholampilo kwenzeka ngaphandle kwelebula, ngokuvamile ngodokotela abathi:

• Ngenisa imikhiqizo ngaphansi kokukhululwa ekusetshenzisweni komuntu siqu

• I-PDRN ehlanganisiwe kuzilungiselelo zekhemisi

• Sebenzisa ukulethwa kwezihloko okusizwa nge-microneedling (okungahlanganisi ukusetshenziswa komjovo)

I-Topical PDRN skincare ilawulwa njengesimonyo futhi ayidingi imvume yangaphambili ye-FDA. Nokho, i I-FDA ayizange isungule i-monograph ye-PDRN, futhi izilinganiso zesisindo samangqamuzana azikho—okusho ukuthi imikhiqizo emibili ebizwa ngokuthi “i-PDRN serum” ingase iqukathe iziqephu ezihluke ngokuphelele .

5. Ukucatshangelwa Kokwakhiwa Kwemikhiqizo Nabakhiqizi

5.1 Isisindo se-Molecular: Ukuguquguquka Okufihliwe

I-Marques Cutoff (1500 kDa) iyi-a indinganiso yegama lamagama,hhayi a ukucaciswa kokwakhiwa. Ukusebenza komtholampilo kuncike ekusabalaliseni kweziqephu, hhayi nje isilinganiso sesisindo samangqamuzana .

Ubufakazi obusuka ku-2018:
Hwang et al. wabonisa lokho uhla olusebenzayo lwezingcezu ze-PDN lubalulekile kwikhwalithi yokuphulukisa isilonda. Kufushane kakhulu: ukuwohloka okusheshayo, akukho siginali eqhubekayo. Inde kakhulu: i-A2A bioavailability encishisiwe, ukuziphatha kokusebenza kufana ne-PN .

Isiqondiso sokwakha:

• Isicelo ukuhlaziywa okugcwele kokusabalalisa izingcezu kusuka kubahlinzeki bempahla eluhlaza

• Yenqaba ukucaciswa okubala kuphela “isilinganiso sesisindo samangqamuzana”

• Ngezinkomba zokulungisa ngemuva kwenqubo, izingcezu zamaketango aphakathi (50–500 kDa) ingase inikeze ukusebenzelana kwe-A2A okuphelele

5.2 Uhlelo Lokulethwa: Okubalulekile Ukumuncwa

I-PDN i i-hydrophilic ne-high-molecular-weight ngokuhlobene nezinto ezivamile zezimonyo. Ukusabalalisa okwenziwa nge-stratum corneum eqinile kuncane .

Amasu okulethwa aqinisekisiwe:

Umthelela womkhiqizo:
Uma wethula “i-serum ye-PDRN yasekhaya,” kufanele noma:

1. Faka imali ku bioavailable fragment engineering (amafrakshini ama-MW aphansi kakhulu), noma

2. Kuvume lokho izithako zemoto (ama-humectants, anti-inflammatories) ashayela izinzuzo zezimonyo ezisheshayo, kanti i-PDRN inikela imiphumela ekhulayo yokuvuselela amaviki kuya ezinyangeni .

6. Imingcele Esafufusa kanye nemibuzo Engaxazululiwe

6.1 I-Vegan/Recombinant PDRN

I-PDRN yendabuko i i-salmon etholakala. Ukukhathazeka ngemvelo, izimiso ze-supply chain, kanye nokungqubuzana kokungezwani nezinhlanzi kukhulise intshisekelo kukho ezinye izindlela ezisuselwe esitshalweni kanye nokuvutshelwa .

Isimo samanje:

• I-Vegan PDRN (i-algae-derived, synthetic biology) iyatholakala ngokwentengiso

• I-Mechanism yakhelwe ukulingisa I-Agonism ye-A2A

• Idatha yesikhathi eside yomtholampilo ayikabi khona

Umbono we-Dermatologist:
"Izinhlobo ze-vegan zidonsa izinsimbi ezifanayo esikhumbeni futhi zinikeza izinzuzo ezifanayo ne-salmon yendabuko ye-PDRN, kodwa azikabi nayo idatha yesikhathi eside yomtholampilo ezisekelayo okwamanje." — UNicole Lee, MD

6.2 I-PDN Emithi Yokwelapha Ehlanganisiwe

Ikusasa le-PDN kungenzeka inhlanganisela, hhayi i-monotherapy.

Ukumatanisa okuvelayo:

• I-PDRN + Exosomes: Uhlelo lwe-AnteAGE's P.E.A.R.L luhlanganisa i-PDRN nama-molecule e-exosome okubonisa ukusetshenziswa kwe-post-microneedling

• I-PDRN + Hyaluronic Acid: Ihlolwe ekusetshenzisweni okuhlangene kanye ne-dermal; i-synergy ebonwe ekwandeni kwe-fibroblast

• I-PDRN + Izici Zokukhula: I-synergy yethiyori; idatha eshicilelwe elinganiselwe

Isizathu somtholampilo:
I-PDRN inikeza i-nucleotide substrate futhi Ukusayina kwe-A2A. Ama-exosomes kanye nezici zokukhula ziyahlinzeka imfundo eyengeziwe ye-cytokine. Lezi okuhambisanayo, ayidingi .

6.3 Uguquko Lwegama Lamabizo: Umthelela Wezohwebo

I-Marques Cutoff injalo ngaphansi konyaka owodwa ubudala. Ukutholwa kumafayili okulawula, ama-pharmacopeia, nezicaciso zentengiso kuzothatha isikhathi .

Ubungozi bemikhiqizo:

• Ukuqhubeka nokulebula i-medium chain PDRN njengokuthi “PN” kungase kumeme ukucutshungulwa kokulawula njengoba izincazelo ziqina

• Ukufuna i-“PDRN” yezingcezwana ezingaphezu kuka-1500 kDa kuphikisana nezinga elikhulayo

• INCI nomenclature ayikabuyekezwa; ukushesha kwezohwebo kuzovuna abamukeli bokuqala bamagama anembile

Isiphetho: I-PDN ku-2026–2027 Treatment Landscape

I-PDRN etholakala ku-Salmon akuyona imfashini. Imile amashumi amathathu eminyaka okunakwa komtholampilo ngezikhathi ezithile ngoba indlela yayo okuyisisekelo sebhayoloji, hhayi kuthrendi .

Iyini i-PDRN:

• I-ejenti yokuvuselela izindlela ezimbili ene ibonise i-A2A agonism kanye ne-salvage pathway bioactivity

• A i-accelerator yangemva kwenqubo osekelwa isilwane nobufakazi bokuhumusha

• A isithako esihlukene ngomehluko ocacile wamangqamuzana ku-PN

Yini i-PDRN engekho:

• Ukuphakanyiswa kobuso okuzimele “kwesimangaliso”

• I-FDA igunyaze umjovo wobuhle e-U.S.

• Impahla ejwayelekile—izindaba zokusabalalisa izingcezu

Kochwepheshe bezobuhle bezokwelapha:

• Linganisa i-PDN njenge- ukuhlanganisa, hhayi esikhundleni

• Beka kuqala ukulethwa kusizwa (i-microneedling, i-laser) ngaphezu kokusebenza kwe-topical ye-passive

• Hlala unolwazi Izimvume ze-NMPA Class III-bazobumba kabusha imakethe yase-Asia ngo-2026-2027

Okwemikhiqizo ye-skincare:

• Hlola i-nomenclature yakho. Ingabe uthengisa i-PDN noma i-PN? Ungakufakazela?

• Uma kwethulwa eChina, hlukanisa amasu akho okulawula umjovo kanye nezimonyo

• Uma wethula i-vegan PDRN, kube obala mayelana nokungabikho kwedatha yokuqhathanisa yesikhathi eside

Izihloko zezindaba ezithi “salmon sperm” zizoqhubeka. Bahlala benza njalo.

Ngemuva kwazo, i-biomolecule esemthethweni iqongelela ubufakazi buthule, icwenge incazelo yayo, futhi ilungiselela isigaba sayo esilandelayo sokuvuthwa emtholampilo.

I-PDRN ifanelwe okungcono kunodumo lwegciwane. Ifanele ukusetshenziswa okunembayo, ukulebula okuyiqiniso, nokuhlanganiswa kuzivumelwano ezivuselelayo ezihlonipha kokubili amandla ayo kanye nemikhawulo yawo.